The impact of health insurance expansion on physician treatment choice: Medicare Part D and physician prescribing
Tóm tắt
Từ khóa
Tài liệu tham khảo
Alpert, A. (2012). The anticipatory effects of medicare part D on drug utilization. Journal of Health Economics, 49, 28–45.
Arrow, K. J. (1963). Uncertainty and the welfare economics of medical care. The American Economic Review, 53(5), 941–973.
Blume-Kohout, M. E., & Sood, N. (2013). Market size and innovation: Effects of medicare part D on pharmaceutical research and development. Journal of Public Economics, 97, 327–336.
Briesacher, B. A., et al. (2011). Medicare part D and changes in prescription drug use and cost burden: National estimates for the medicare population, 2000 to 2007. Medical Care, 49(9), 834–841.
Bryant, E. E., & Shimizu, I. (1988). Sample design, sampling variance, and estimation procedure for the national abulatory medical care survey. Vital and Health Statistics. Series 2. Data Evaluation and Methods Research, 108, 1–39.
Card, D., Dobkin, C., & Maestas, N. (2009). Does Medicare Save Lives? The Quarterly Journal of Economics, 124(2), 597–636.
Chalkley, M., & Malcomson, J. M. (1998). Contracting for health services when patient demand does not reflect quality. Journal of Health Economics, 17(1), 1–19.
Charlson, M. E., et al. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40(5), 373–383.
Chay, K.Y., Kim, D. & Swamina, S., 2010. Medicare, hospital utilization and mortality: Evidence from the program’s origins. Working Paper.
Duggan, M., & Morton, F. S. (2010). The effect of medicare part D on pharmaceutical prices and utilization. American Economic Review, 100(1), 590–607.
Duggan, M. G., & Morton, F. S. (2011). The medium-term impact of medicare part D on pharmaceutical prices. American Economic Review, 101(3), 387–392.
Ellis, R. P., & McGuire, T. G. (1986). Provider behavior under prospective reimbursement. Journal of Health Economics, 5(2), 129–151.
Engelberg, J., Parsons, C. A., & Tefft, N. (2013). First, do no harm: Financial conflicts in medicine. Working Paper.
Engelhardt, G. V., & Gruber, J. (2011). Medicare Part D and the financial protection of the elderly. American Economic Journal: Economic Policy, 3(4), 77–102.
Epstein, A. J., & Ketcham, J. D. (2014). Information technology and agency in physicians’ prescribing decisions. The RAND Journal of Economics, 45(2), 422–448.
Federman, A. D. (2004). Don’t ask, don’t tell: The status of doctor-patient communication about health care costs. Archives of Internal Medicine, 164(16), 1723–1724.
Feldstein, M. S. (1970). The rising price of physicians’ services. The Review of Economics and Statistics, 52(2), 121–133.
Grembi, V., Nannicini, T., & Troiano, U. (2011). Do fiscal rules matter? A difference-in-discontinuities design. Working Paper.
Imbens, G. W. (2008). Regression discontinuity designs: A guide to practice. Journal of Econometrics, 142(2), 615–635.
Kaestner, R., & Khan, N. (2012). Medicare part D and its effect on the use of prescription drugs and use of other health care services of the elderly. Journal of Policy Analysis and Management, 31(2), 253–279.
Kaestner, R., Long, C., & Alexander, G. C. (2014). Effects of prescription drug insurance on hospitalization and mortality: Evidence from medicare part D. NBER Working Paper Series, (19948).
Ketcham, J. D., & Simon, K. I. (2008). Medicare part D’s effects on elderly patients’ drug costs and utilization. The American Journal of Managed Care, 14(11 Suppl), SP14–SP22.
Lakdawalla, D., Sood, N., & Gu, Q. (2013). Pharmaceutical Advertising and Medicare Part D. Journal of Health Economics, 32(6), 1356–67.
Lee, D. S., & Lemieux, T. (2010). Regression discontinuity designs in economics. Journal of Economic Literature, 48(2), 281–355.
Lichtenberg, F. R., & Sun, S. X. (2007). The impact of medicare part D on prescription drug use by the elderly. Health affairs (Project Hope), 26(6), 1735–1744.
Liu, F. X., et al. (2011). The impact of medicare part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility. Health Services Research, 46(4), 1104–1123.
Lurie, N., et al. (1990). Pharmaceutical Representatives in academic medical centers: Interaction with faculty and housestaff. Journal of General Internal Medicine, 5(3), 240–243.
McCrary, J. (2008). Manipulation of the running variable in the regression discontinuity design: A density test. Journal of Econometrics, 142(2), 698–714.
Meyers, D. S., et al. (2006). Primary care physicians’ perceptions of the effect of insurance status on clinical decision making. Annals of Family Medicine, 4(5), 399–402.
Sacks D.W. (2013). Physician agency, compliance, and patient welfare?: Evidence from anti-cholesterol drugs. Working Paper.
The Henry J. Kaiser Family Foundation (2003). The medicare prescription drug benefit fact sheet,
The Henry J. Kaiser Family Foundation (2006). The medicare prescription drug benefit fact sheet,
The Henry J. Kaiser Family Foundation (2007a). Medicare spending and financing fact sheet,
The Henry J. Kaiser Family Foundation (2007b). The medicare prescription drug benefit fact sheet
The Henry J. Kaiser Family Foundation (2010). The medicare prescription drug benefit fact sheet.
Weisbrod, B. A. (1991). The health care quadrilemma: An essay on technological change, insurance, quality of care, and cost containment. Journal of Economic Literature, 29(2), 523–552.
Wynia, M. K., et al. (2003). Do physicians not offer useful services because of coverage restrictions? Health Affairs (Project Hope), 22(4), 190–197.
Yin, W., et al. (2008). The effect of the medicare part D prescription benefit on drug utilization and expenditures. Annals of Internal Medicine, 148(3), 169–177.